Institut de Neurosciences Cognitives et Intégratives d'Aquitaine (UMR5287)

Aquitaine Institute for Cognitive and Integrative Neuroscience



INCIA - UMR 5287- CNRS
Université de Bordeaux

Zone nord Bat 2 2ème étage
146, rue Léo Saignat
33076 Bordeaux cedex
France

Téléphone 05.57.57.15.51
Télécopie 05.56.90.14.21

Supervisory authorities

CNRS Ecole Pratique des Hautes Etudes Université de Bordeaux

Our partners

Neurocampus Unitéde Formation de Biologie

GDR

GDR Robotique GDR Mémoire GDR Multi-électrodes

Search




Home > News

NARSAD Independent Investigator Grant for Mathieu Wolff

by Wolff - published on

NARSAD Independent Investigator Grant for Mathieu Wolff

Mathieu Wolff, from team DECAD, was awarded a 100k$ independent investigator grant from the Brain & Behavior Research Foundation (formerly NARSAD, National Alliance for Research on Schizophrenia and Depression).

The proposed work aims to elucidate the functional contribution of thalamic dysfunctions in the cognitive symptoms associated with schizophrenia. The reuniens thalamic nucleus will be central in this project, due to its specific connectivity with the medial prefrontal cortex and the hippocampus. In particular, the effect of chronic activation/inactivation of this structure will be examined in the Rat with a range of electrophysiological, chemogenetic and behavioural techniques.

Check on the Brain&Behavior Research Foundation website


Thalamic Determinants of Schizophrenia Pathophysiology
“Mathieu Wolff, Ph.D., University of Bordeaux, France, will investigate brain areas possibly involved in generating cognitive symptoms of schizophrenia, which are not sufficiently relieved by current treatment options. Dr. Wolff will focus on the brain’s medial prefrontal cortex and hippocampus. The team will interfere with cells that connect to those regions and then test for any resulting changes in the activity of both brain regions. They will also test for any resulting cognitive impairment and try to reverse the disruption to the target group of cells. Their findings will help determine the role, and potential therapeutic value, of these cells in schizophrenia.”